Last updated: February 27, 2026
What is the excipient profile of DAYPRO?
DAYPRO, an approved non-steroidal anti-inflammatory drug (NSAID) containing mefenamic acid, involves excipients that influence its stability, bioavailability, and patient tolerability. Common excipients in DAYPRO formulations include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. These excipients are selected for their inertness, compressibility, and ability to optimize tablet disintegration and dissolution.
How do excipients impact DAYPRO’s formulation?
Excipients optimize manufacturing and drug performance through various roles:
- Fillers and diluents (e.g., lactose monohydrate): Provide volume and aid compression.
- Disintegrants (e.g., croscarmellose sodium): Facilitate rapid breakdown of tablets in the GI tract to enhance absorption.
- Binders (e.g., microcrystalline cellulose): Improve tablet cohesion.
- Lubricants (e.g., magnesium stearate): Reduce tooling wear and improve flow.
The selection and proportion of these excipients influence bioavailability, stability, and patient compliance.
What are strategic considerations for excipient selection in DAYPRO?
Selecting excipients involves evaluating their effect on:
- Bioavailability: Excipients that enhance dissolution of mefenamic acid can improve absorption and therapeutic effect.
- Stability: Excipients must avoid interacting with mefenamic acid to prevent degradation.
- Tolerability: Excipients should reduce gastrointestinal discomfort, a common side effect for NSAIDs.
- Manufacturing: Compatibility with high-speed tablet production and cost-efficiency.
There is potential to develop formulations with super-disintegrants or novel excipients that enable lower doses or alternative delivery routes.
What commercial opportunities exist with excipient innovation?
Innovation in excipients can open multiple avenues:
1. Developing Solubility-Enhancing Excipients
- Use of surfactants or complexing agents to increase mefenamic acid solubility.
- Potential for oral thin films or dispersible tablets, expanding patient populations, including pediatrics.
2. Reducing Gastrointestinal Side Effects
- Incorporation of gastroprotective excipients such as alginates or barrier agents.
- Opportunities for differentiating formulations that minimize NSAID-associated ulcers.
3. Formulation Differentiation with Novel Excipients
- Use of multifunctional excipients that combine disintegration, taste-masking, and stability at reduced excipient loads.
- Expansion into controlled-release or targeted delivery systems.
4. Licensing and Co-Formulation
- Partnering with excipient manufacturers to develop proprietary blends.
- Co-formulating DAYPRO with other analgesics or gastrointestinal protectants for combination therapy.
5. Custom Manufacturing for Generic Entry
- Tailoring excipient combinations to meet regulatory standards for generic versions.
- Achieving cost advantages through optimized formulations.
What regulatory considerations apply?
Regulatory agencies like the FDA and EMA emphasize excipient safety, especially for new formulations or routes. Excipients must meet pharmacopeial standards, demonstrate inertness, and avoid interactions. For combination or novel excipients, extensive safety data and bioequivalence studies are necessary.
How do competitive dynamics influence excipient strategy?
- Patent protection periods incentivize innovation in formulation chemistry and excipient use.
- Patent designs may focus on novel excipient combinations for extended exclusivity.
- Outsourcing manufacturing and licensing to excipient specialists can accelerate new product launches.
What are the prominent excipient suppliers for NSAIDs?
Leading excipient suppliers include:
| Supplier |
Product Types |
Application in NSAID formulations |
| Colorcon |
Disintegrants, binders, film coatings |
Tablet formulation, taste-masking |
| FMC Corporation |
Fillers, emulsifiers, antioxidants |
Stability enhancement, dosage form design |
| BASF SE |
Disintegrants, lubricants, coatings |
Controlled-release formulations |
| Dow Chemical (formerly DuPont) |
Inert binders, stabilizers |
Enhancing shelf life, bioavailability |
Conclusion
Excipient strategy for DAYPRO hinges on optimizing bioavailability, reducing side effects, and enabling formulation innovation. The landscape offers opportunities for solubility enhancement, tolerability improvements, and combination therapies. Collaborations with excipient manufacturers and regulatory compliance are crucial to capitalize on these opportunities.
Key Takeaways
- DAYPRO’s excipient profile influences manufacturing, stability, and patient experience.
- Strategy focuses on enhancing absorption, minimizing side effects, and enabling new formulations.
- Innovation in excipients offers potential for differentiation and expanded patient access.
- Regulatory standards demand thorough safety and interaction assessments.
- Market dynamics favor partnerships with excipient suppliers to accelerate development.
FAQs
1. Can excipient modifications improve DAYPRO’s bioavailability?
Yes, excipients such as surfactants or complexing agents can increase solubility and absorption of mefenamic acid.
2. What excipients are used to reduce gastrointestinal irritation?
Excipients like gastroprotective agents (e.g., alginates) or barrier-forming polymers are incorporated to mitigate irritation.
3. Are novel excipients needed for new DAYPRO formulations?
Potentially, especially for innovative delivery systems like dispersible tablets or films, which require excipients optimizing disintegration and taste.
4. How do excipient choices impact regulatory approval?
Excipients must meet safety standards and demonstrate no adverse interactions; novel excipients require additional safety data.
5. What opportunities exist for licensing excipient-based innovations?
Opportunities include licensing proprietary excipient blends, co-formulation with other drugs, or developing specialized delivery platforms.
References
[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Testing of Orally Inhaled Drugs.
[2] European Medicines Agency. (2018). Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medicinal Product.
[3] Lindert, C., et al. (2018). Enhancing Drug Solubility and Bioavailability Using Novel Excipients. Journal of Pharmaceutical Sciences, 107(9), 2237-2245.
[4] U.S. Pharmacopoeia. (2022). Excipients Monographs.
